The pharmacist becomes an entrepreneur: eyes focused on bargaining and economic-financial management. Without forgetting that the law requires clear indications for the customer. Which, however, it is not known how many benefits it will derive from liberalization<\/p>\n
Over-the-counter drugs, green light to prices. After 2007, the year of "interregnum" which maintained a maximum reference for each product, from January 2008 the sale price of Otc and Sop will be established independently by each exercise. A sort of Copernican revolution for the pharmacist, used to reasoning on a fixed final rate, from which he often started to calculate top-ups and possible discounts. The imperative is to change the logic FSexplains Ezio Diolaiti, deputy general manager of Unico, the third largest pharmaceutical distributor in Italy: \u00abSome pharmacists feel lost in the absence of a reference price, because they think it is useful for negotiating better with suppliers, but it is a problem psychological. The pharmacist will have to start thinking about the purchase price, which is different in each point of sale, because the supplier's conditions of sale are different; after having examined his management costs, he will have to decide on the mark-up to apply. Bearing in mind that price liberalization does not necessarily mean lower prices. We have been teaching CME courses on pricing techniques and economic-financial management for more than a year. A stimulus for pharmacists to better understand this aspect of their work. Six months ago we published a booklet with a slide rule (which, starting from the purchase price, once the mark-up has been decided, gives me the sale price) and we will come back with operations of this type\u00bb. Dr. Carlo Benzi, owner of a Milanese pharmacy, is not upset: \u00abIt will simply be a matter of thinking about the top-up, as it should already be done with parapharmaceuticals, and as all traders do. The only problem is that the packs will arrive without a price and you will have to affix it or make a price list for the public. Then there will be seasonal discounts, or rather, since it no longer makes sense to talk about discounts in the absence of a final price, promotions. There are management software that establish what the mark-up must be to reach the break-even point. In short, the pharmacist will have to become a little more of an entrepreneur. The negotiation phase is very important: I had to change my way of working, but the results can be seen\u00bb. \u00abIt should be borne in mind\u00bb, recalls Stefano Brovelli, Bayer's consumer care division director, \u00abthat over-the-counter medicines do not all have the same mark-up, but, depending on the category, there are different discount policies, which can range from 25 to 60-70%. So the pharmacy will need to account for a different margin structure for different competitive scenarios. He will be able to work by category (throat, antifungals, analgesics, etc.), remembering that OTC itself is not a category. Furthermore, within the category, it will have to take into account the particular competitive situation of the leading brands. Then the pharmacist, who has to manage more than a thousand references, will have to decide whether to define prices once a year, calibrating the final price on an average purchase price. For its part, it is desirable for the industry to implement a choice of transparency, making its own sale price clear". Diolaiti continues: \u00abStarting from this year, in our price lists we already think on the basis of the net purchase price. After all, the fixed price helps the discount policy which I think is a loser for the pharmacy. Large-scale distribution uses the over-the-counter drug as a red herring to complete the assortment, and offers discounts that it does not have if<\/p>","protected":false},"excerpt":{"rendered":"
Il farmacista diventa imprenditore: occhi puntati su contrattazione e gestione economico-finanziaria. Senza dimenticare che la legge impone indicazioni chiare per il cliente. Il quale, però, non si sa quanti benefici trarrà dalla liberalizzazione Farmaci da banco, via libera ai prezzi. Dopo il 2007, anno di "interregno" che manteneva un riferimento massimo per ogni prodotto, …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-11730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/11730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=11730"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/11730\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=11730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=11730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=11730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}